Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions
Cancer Letters · 2024-11 · 604 · 217241
DOI: 10.1016/j.canlet.2024.217241 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-11. Verfasst von Xiaoyu Gang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenyang Science and Technology Bureau, Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program, Guangzhou University of Chinese Medicine International Institute for Translational Chinese Medicine.
Abstract (Originalsprache)
Immunotherapy, remarkably immune checkpoint inhibitors (ICIs), has significantly altered the treatment landscape for non-small cell lung cancer (NSCLC). Despite their success, the discontinuation of ICIs therapy may occur due to factors such as prior treatment completion, disease progression during ICIs treatment, or immune-related adverse events (irAEs). As numerous studies highlight the dynamic nature of immune responses and the sustained benefits of ICIs, ICIs rechallenge has become an attractive and feasible option. However, the decision-making process for ICIs rechallenge in clinical settings is complicated by numerous uncertainties. This review systematically analyses existing clinical research evidence, classifying ICIs rechallenge into distinct clinical scenarios, exploring methods to overcome ICIs resistance in rechallenge instances, and identifying biomarkers to select patients likely to benefit from rechallenge. By integrating recent studies and new technologies, we offer crucial recommendations for future clinical trial design and provide a practical guideline to maximize the therapeutic benefits of immunotherapy for NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.
- Clinical Medicine, Shenyang Medical College, Shenyang, 110001, China.
- Psychological Medicine, Shenyang Medical College, Shenyang, 110001, China.
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China; Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial K…
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China. Electronic address: zhaomf618@126.com.
Förderung
- Shenyang Science and Technology Bureau
- Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program
- Guangzhou University of Chinese Medicine International Institute for Translational Chinese Medicine
- Foundation of Liaoning Province Education Administration
- Key Technologies Research and Development Program
- Liaoning Planning Office of Philosophy and Social Science
- National Natural Science Foundation of China
Zitieren
APA
Gang, X., Yan, J., Li, X., Shi, S., Xu, L., Liu, R., Cai, L., Li, H., & Zhao, M. (2024). Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions. Cancer Letters, 604, 217241. https://doi.org/10.1016/j.canlet.2024.217241
Vancouver
Gang X, Yan J, Li X, Shi S, Xu L, Liu R, et al. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions. Cancer Letters. 2024;604:217241. doi:10.1016/j.canlet.2024.217241
BibTeX
@article{Gang2024,
author = {Gang, Xiaoyu and Yan, Jinshan and Li, Xin and Shi, Sha and Xu, Lu and Liu, Ruotong and Cai, Lutong and Li, Heming and Zhao, Mingfang},
title = {Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions},
journal = {Cancer Letters},
year = {2024},
volume = {604},
pages = {217241},
doi = {10.1016/j.canlet.2024.217241}
}
EUVIMED